ArticleArchives of toxicology2026
Histone deacetylase 6 (HDAC6)-mediated α-tubulin (K40) deacetylation and microtubule destabilization disrupt autophagosome-lysosome fusion in PBDE-47-induced neurotoxicity.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
2,2',4,4'-tetrabromodiphenyl ether (PBDE-47) is a pervasive environmental brominated flame retardant that accumulates in nervous tissues and induces persistent neurotoxicity. Emerging evidence indicates that PBDE-47 perturbs neuronal autophagy, yet the definitive upstream molecular mechanism remains uncharacterized, hindering the development of effective protective strategies. This study was performed to clarify the toxic regulatory cascade and explore feasible pharmacological interventions using in vivo neonatal rat hippocampal tissue and in vitro PC12 neuronal cell models. Animals were neonatally exposed to PBDE-47 (0.1, 1.0, 10.0 mg/kg·bw), and PC12 cells were treated with PBDE-47 (1, 10, 20 µM) for mechanistic exploration. Results showed that PBDE-47 dose-dependently upregulated histone deacetylase 6 (HDAC6), decreased α-tubulin (K40) acetylation, and destabilized neuronal microtubules. Such microtubule structural damage impaired autophagosome retrograde trafficking, blocked autophagosome-lysosome fusion, and eventually caused neuronal loss, synaptic protein reduction, and cognitive impairment. For mechanism validation and rescue experiments, 1 mg/kg·bw paclitaxel (PTX) and 1 mg/kg·bw tubastatin A (TBA) were administered to neonatal rats, whereas 12.5 nmol/L PTX and 10 µmol/L TBA were used for PC12 cell treatment to stabilize microtubules and selectively inhibit HDAC6, respectively. Both pharmacological interventions effectively restored tubulin acetylation, rescued defective autophagic flux, and mitigated PBDE-47-induced neuronal injury, with TBA showing better applicability due to its high blood-brain barrier permeability and biosafety. Behavioral tests in vivo verified that PTX and TBA treatment significantly ameliorated PBDE-47-elicited learning and memory deficits. Collectively, these findings define the HDAC6/microtubule acetylation axis as a core upstream pathway responsible for PBDE-47-triggered autophagic transport failure and neurotoxicity, providing robust experimental evidence and a promising therapeutic target for the prevention of PBDEs-mediated neurological disorders.
Indexed as
Identifiers
42919942What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.